在皮肤科药物唾手可得的今天，混乱的自我药疗成为了疾病管理的"放大器"。"在药店柜台与网络平台 上，各类'皮肤神膏'唾手可得。"一位业内专家评论道，"监管的灰色地带与商业的过度营销，共同构筑 了激素滥用的温床。"与此同时，"谈激素色变"的恐慌又让部分患者拒绝一切必要治疗，导致病情失 控。 监管的灰色地带与商业的过度营销，共同构筑了激素滥用的温床 当"一抹就退"的激素药膏成为无数家庭的首选，特应性皮炎的治疗也陷入了一场恶性循环：瘙痒、用 药、缓解、复发、加重……再用药。如今，一款国产创新药，试图为这场漫长的斗争画上休止符。 "我的病人里，特应性皮炎约占三分之二，其中激素滥用的情况触目惊心。"11月22日，北京大学人民医 院皮肤科张建中教授在"首届湿疹之友健康管理论坛"上表示，"他们自行购药，随意涂抹，后果很严重 ——不可逆的膨胀纹、激素依赖性皮炎，这些都已成为皮肤科门诊的常见'后遗症'。" 监管灰色地带与患者的自救困局 特应性皮炎（AD），这种被俗称为"过敏性湿疹"的疾病，远非简单的皮肤问题。它是一种慢性、复发 性、炎症性皮肤病，常与过敏性鼻炎、哮喘等结伴而行，被视为一种系统性疾病。全球范围内，AD的 发病率持续 ...

Investment Rating - The report does not explicitly state an investment rating for the eczema ointment industry Core Insights - The Chinese eczema ointment market is characterized by a growing demand for innovative solutions that balance efficacy and safety, driven by a trend of patient consumerization and the prevalence of unsafe products containing illegal additives [3][5] - The report emphasizes that only products with the "National Drug Approval Number" can ensure safety and efficacy, highlighting the non-hormonal innovative drug, Zeli Mei® (Benvimod Ointment), as a representative of the future market direction [3][8] Summary by Sections Market Overview - Eczema is a chronic, recurrent, itchy, and inflammatory skin disease affecting 15% to 30% of dermatology patients [13][29] - Topical medications account for 67% of eczema treatments, with non-hormonal topical agents becoming increasingly important due to the potential adverse effects of long-term steroid use [13][30] - The market for eczema ointments is projected to grow from approximately 5.5 billion yuan in 2019 to 7.44 billion yuan by 2029, with a compound annual growth rate (CAGR) of 7.5% from 2025 to 2029 [43][45] Product Categories and Efficacy Analysis - The report identifies various types of topical agents and their effectiveness, noting that treatment strategies should be adjusted based on the stage of eczema: acute, subacute, and chronic [47][52] - Non-hormonal innovative drugs like Benvimod Ointment are highlighted for their clinical advantages in efficacy and safety compared to traditional treatments [30][33] Patient Behavior and Awareness - Patients prioritize ingredient safety and brand reputation when purchasing eczema medications, with a significant shift towards online and branded channels for drug acquisition [6][36] - The consumerization of healthcare is evident, with patients actively seeking information and making informed decisions about their treatments [40][41] Market Challenges and Regulatory Landscape - The report discusses the prevalence of misleading marketing and unsafe products in the eczema ointment market, emphasizing the need for strict regulatory compliance and consumer education [7][8] - The "National Drug Approval Number" is presented as a critical standard for ensuring the safety and efficacy of eczema treatments, with a trend towards increased regulatory scrutiny [8][43]

Investment Rating - The report does not explicitly state an investment rating for the eczema ointment market in China Core Insights - The Chinese eczema ointment market is characterized by a growing demand for innovative solutions that balance efficacy and safety, driven by a trend of patient consumerization and the prevalence of unsafe products containing illegal hormone additives [5][7] - The report emphasizes that only products with the "National Drug Approval Number" can ensure safety and efficacy, highlighting the innovative non-hormonal drug, Zeli Mei® (Benvimod Cream), as a representative of future market direction [5][10] Summary by Sections Market Overview - Eczema is a chronic, recurrent inflammatory skin disease affecting 15% to 30% of dermatology patients, with topical medications accounting for 67% of treatment options [15][25] - Non-hormonal topical agents are crucial due to the potential adverse effects of long-term steroid use, with Benvimod Cream showing significant clinical advantages in efficacy and safety [15][21] Product Categories and Efficacy Analysis - The report outlines the importance of recognizing "National Drug Approval Number" products as the only legally validated treatment for eczema, with a focus on innovative drugs that enhance both efficacy and safety [10][42] - The market is transitioning from traditional to innovative drugs, with a notable increase in online pharmacy sales, reaching 1.78 billion yuan in Q2 2025, a year-on-year growth of over 37% [35][42] Patient Behavior and Awareness - The primary demographics of eczema patients in China are children (ages 2-12) and young adults (ages 18-60), with nearly 90% of cases being mild to moderate [48][54] - Patients prioritize ingredient safety and brand reputation when purchasing topical medications, with over 40% avoiding steroid treatments due to concerns about side effects [48][60] - The digital healthcare landscape is evolving, with e-commerce becoming a significant growth driver for dermatological products, as online medical consultations are increasingly popular [61][62] Market Issues and Analysis - The report identifies significant market issues, including the prevalence of misleading advertising and unsafe products, which pose serious health risks to consumers, particularly infants [9][10] - It stresses the need for strict regulatory measures to eliminate non-compliant products and promote a market focused on innovative, compliant drugs [10][42]